Limer 1M Tablet PR contains a combination of Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. This dual mechanism addresses both insulin deficiency and insulin resistance, providing effective glycemic control. Limer 1M Tablet PR is prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on monotherapy or lifestyle modifications alone. The prolonged-release formulation ensures a steady plasma concentration, minimizing fluctuations and improving patient compliance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, typically transient and dose-related. Rarely, hypoglycemia may occur, primarily due to the sulfonylurea component, necessitating caution in dose titration and monitoring. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to any component. Regular monitoring of blood glucose, renal function, and lactic acid levels is recommended during therapy. Limer 1M Tablet PR should be used under medical supervision with appropriate lifestyle interventions to optimize therapeutic outcomes in type 2 diabetes management.